CA: A Cancer Journal for Clinicians最新文献

筛选
英文 中文
Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision 早期非小细胞肺癌:迈向生物精准时代的风险适应范式。
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-09-09 DOI: 10.3322/caac.70100
Chaoqi Zhang MD, PhD, 张超奇, Xuanyu Gu MD, 谷炫谕, Pan Wang MD, 王攀, Dongyu Li MD, 李东宇, Guochao Zhang MD, 张国超, Ting Wang MD, PhD, 王婷, Peng Wu PhD, 吴芃, Wei Rao MD, 饶薇, Shan Muhammad PhD, Binghua Tan MD, 谭炳华, Yun Che MD, PhD, 车云, Mobai Zhu MD, 朱墨白, Qilin Qiao MD, 乔奇临, Fanbo Lai MD, 来凡博, Bohui Zhao MD, 赵博慧, Kailun Fei MD, 费凯伦, Yue Wu PhD, 吴玥, Zhihui Zhang PhD, 张志慧, Min Dai PhD, 代敏, Wanqing Chen MD, PhD, 陈万青, Yawei Zhang PhD, 张亚玮, Nan Bi MD, 毕楠, Jie Wang MD, 王洁, Jie He MD, PhD, 赫捷
{"title":"Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision","authors":"Chaoqi Zhang MD, PhD,&nbsp;张超奇,&nbsp;Xuanyu Gu MD,&nbsp;谷炫谕,&nbsp;Pan Wang MD,&nbsp;王攀,&nbsp;Dongyu Li MD,&nbsp;李东宇,&nbsp;Guochao Zhang MD,&nbsp;张国超,&nbsp;Ting Wang MD, PhD,&nbsp;王婷,&nbsp;Peng Wu PhD,&nbsp;吴芃,&nbsp;Wei Rao MD,&nbsp;饶薇,&nbsp;Shan Muhammad PhD,&nbsp;Binghua Tan MD,&nbsp;谭炳华,&nbsp;Yun Che MD, PhD,&nbsp;车云,&nbsp;Mobai Zhu MD,&nbsp;朱墨白,&nbsp;Qilin Qiao MD,&nbsp;乔奇临,&nbsp;Fanbo Lai MD,&nbsp;来凡博,&nbsp;Bohui Zhao MD,&nbsp;赵博慧,&nbsp;Kailun Fei MD,&nbsp;费凯伦,&nbsp;Yue Wu PhD,&nbsp;吴玥,&nbsp;Zhihui Zhang PhD,&nbsp;张志慧,&nbsp;Min Dai PhD,&nbsp;代敏,&nbsp;Wanqing Chen MD, PhD,&nbsp;陈万青,&nbsp;Yawei Zhang PhD,&nbsp;张亚玮,&nbsp;Nan Bi MD,&nbsp;毕楠,&nbsp;Jie Wang MD,&nbsp;王洁,&nbsp;Jie He MD, PhD,&nbsp;赫捷","doi":"10.3322/caac.70100","DOIUrl":"10.3322/caac.70100","url":null,"abstract":"<p>The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence–driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for high-risk individuals while permitting safe de-escalation for those at low risk. This holistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures for patients with early stage nonsmall cell lung cancer.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 5","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva 新的(版本9)美国癌症联合委员会(AJCC)肿瘤-淋巴结-转移(TNM)分期方案的外阴癌
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-08-28 DOI: 10.3322/caac.70104
Alexander B. Olawaiye MD, Elliot A. Asare MD, MS, Ian S. Hagemann MD, PhD, Priya R. Bhosale MD, MBA, Stephanie Gaillard MD, PhD, Brian Rous MBBChir, PhD, Bunja Rungruang MD, Shitanshu Uppal MD, MBA, Gulisa Turashvili MD, PhD, Kaled M. Alektiar MD, Jonathan A. Cosin MD, Uma Krishnamurti MD, PhD, Lee-may Chen MD, Keiichi Fujiwara MD, PhD, Matthew A. Powell MD, Mauricio A. Cuello MD, PhD, David G. Mutch MD
{"title":"The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva","authors":"Alexander B. Olawaiye MD,&nbsp;Elliot A. Asare MD, MS,&nbsp;Ian S. Hagemann MD, PhD,&nbsp;Priya R. Bhosale MD, MBA,&nbsp;Stephanie Gaillard MD, PhD,&nbsp;Brian Rous MBBChir, PhD,&nbsp;Bunja Rungruang MD,&nbsp;Shitanshu Uppal MD, MBA,&nbsp;Gulisa Turashvili MD, PhD,&nbsp;Kaled M. Alektiar MD,&nbsp;Jonathan A. Cosin MD,&nbsp;Uma Krishnamurti MD, PhD,&nbsp;Lee-may Chen MD,&nbsp;Keiichi Fujiwara MD, PhD,&nbsp;Matthew A. Powell MD,&nbsp;Mauricio A. Cuello MD, PhD,&nbsp;David G. Mutch MD","doi":"10.3322/caac.70104","DOIUrl":"https://doi.org/10.3322/caac.70104","url":null,"abstract":"<p>The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging for all cancer sites has been updated periodically as a published manual for many years. The last update of the manual version, the eighth edition <i>AJCC Cancer Staging Manual</i>, went into use on January 1, 2018. The AJCC has since restructured and updated its processes for curating, analyzing, and publishing updates to the TNM staging system. All AJCC staging-related data are now housed on its new application programming interface. Consequently, the subsequent AJCC TNM staging updates are now published electronically as protocols and are released by disease sites. The protocol for carcinoma of the vulva, AJCC version 9, is now published. The new TNM vulvar cancer staging was validated using the American College of Surgeons’ National Cancer Data Base. This article highlights the changes to the new AJCC TNM staging protocol for carcinoma of the vulva; these changes align with the 2021 International Federation for Gynecology and Obstetrics staging. The most important of the changes are: (1) a new method for depth of invasion measurement, (2) the addition of a new T subcategory—T4, (3) redefined N subcategories, and (4) an increased number of M subcategories with the addition of <i>clinical</i> to all M subcategories.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 5","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thank You to Reviewers 2026 感谢评论者2026
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-08-28 DOI: 10.3322/caac.70108
{"title":"Thank You to Reviewers 2026","authors":"","doi":"10.3322/caac.70108","DOIUrl":"https://doi.org/10.3322/caac.70108","url":null,"abstract":"<p>In order to maintain the high standards of <i>CA</i>’s content, the Editors of <i>CA</i> rely on the knowledge and dedication of many experts in deciding which topics to pursue, which manuscripts to publish, and what modifications to make to ensure medical and scientific accuracy and suitability for our readers. We thank our Associate Editors and our Editorial Advisory Board, who continue to provide these services for us time and time again.</p><p>We are also greatly indebted to the effort and expertise of the following individuals for reviewing manuscripts for the journal from July 1, 2025, to June 30, 2026. These individuals go beyond expectations by consistently and expeditiously delivering comprehensive, discerning reviews.</p><p>Nadeem R. Abu-Rustum</p><p>Pedro Barata</p><p>Surinder Batra</p><p>Beth Beadle</p><p>Daniel Benedetti</p><p>Sushil Beriwal</p><p>Stephanie Blank</p><p>Susana Campos</p><p>Fumiko Chino</p><p>Clay Cockerell</p><p>Adil Daud</p><p>Michael Davies</p><p>Ajay Dhakal</p><p>Jessica DiSilvestro</p><p>Milana Dolezal</p><p>Julien Edeline</p><p>Bita Esmaeli</p><p>Douglas Evans</p><p>Vaia Florou</p><p>Zhi Ven Fong</p><p>Anand Ganesan</p><p>Ben George</p><p>Amandeep Godara</p><p>Krishna Gunturu</p><p>Lindsay Hannan</p><p>Jeremy Harris</p><p>Kate Hetherington</p><p>Kathleen Horst</p><p>Fernando Hugo</p><p>Ahmedin Jemal</p><p>Rachel Jimenez</p><p>Corinne Joshu</p><p>Hina Khan</p><p>Albert E. Kim</p><p>Kevin B. Kim</p><p>Matthew Kudek</p><p>Matteo Lambertini</p><p>Phebe Lemert</p><p>Gilberto Lopes de Lima Lopes Junior</p><p>Stefano Luminari</p><p>Martin Ma</p><p>Kim Margolin</p><p>Carol Marquez</p><p>Jonathan Marron</p><p>Claudia Massarotti</p><p>Paul Mathew</p><p>Clarissa Mathias</p><p>Sandy Mazzoni</p><p>Krishnan Patel</p><p>Mack Roach</p><p>Ilana Schlam</p><p>Vivek Subbiah</p><p>Molly Taylor</p><p>Derek Tsang</p><p>Angela E. Usher</p><p>Hao Wang</p><p>Lori Wirth</p><p>Fabio Ynoe de Moraes</p><p>Youssef Zeidan</p><p>Mu-Sheng Zeng</p><p>Janie Zhang</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 5","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer 不利的中危局限性前列腺癌中不一致的分子生物标志物。
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-08-24 DOI: 10.3322/caac.70105
Michael Rooney MD, MS, Krishnan R. Patel MD, MHS, Shalin Shah MD, Justin R. Gregg MD, Steven Jay Frank MD, Karen Hoffman MD, MHSc, MPH, Ryan Park MD, Comron J. Hassanzadeh MD, MPH, Seungtaek Choi MD, Sean McGuire MD, PhD, Quynh-Nhu Nguyen MD, Daniel N. Costa MD, Patricia Troncoso MD, Sumit K. Subudhi MD, Shuang George Zhao MD, PhD, Curtis A. Pettaway MD, Paul Corn MD, PhD, Chad Tang MD, Phuoc T. Tran MD, PhD
{"title":"Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer","authors":"Michael Rooney MD, MS,&nbsp;Krishnan R. Patel MD, MHS,&nbsp;Shalin Shah MD,&nbsp;Justin R. Gregg MD,&nbsp;Steven Jay Frank MD,&nbsp;Karen Hoffman MD, MHSc, MPH,&nbsp;Ryan Park MD,&nbsp;Comron J. Hassanzadeh MD, MPH,&nbsp;Seungtaek Choi MD,&nbsp;Sean McGuire MD, PhD,&nbsp;Quynh-Nhu Nguyen MD,&nbsp;Daniel N. Costa MD,&nbsp;Patricia Troncoso MD,&nbsp;Sumit K. Subudhi MD,&nbsp;Shuang George Zhao MD, PhD,&nbsp;Curtis A. Pettaway MD,&nbsp;Paul Corn MD, PhD,&nbsp;Chad Tang MD,&nbsp;Phuoc T. Tran MD, PhD","doi":"10.3322/caac.70105","DOIUrl":"10.3322/caac.70105","url":null,"abstract":"&lt;p&gt;A Black gentleman aged 67 years was referred for evaluation of an elevated prostate-specific antigen (PSA) level of 4.9 ng/mL detected during routine screening, representing an increase from a prior value of 3.6 ng/mL 1 year earlier and a gradual rise from values in the low 2 ng/mL range beginning in his mid-50s. He reported no lower urinary tract symptoms and had an Eastern Cooperative Oncology Group performance status of 0. His past medical history was notable only for well controlled hypertension and hyperlipidemia. He had no family history of prostate cancer. He remained physically active and had an estimated life expectancy exceeding 10 years based on actuarial life tables,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; with both parents having lived into their late 80s. His American Urological Association International Prostate Symptom Score was 6, and his score on the Sexual Health Inventory for Men was 19. Digital rectal examination revealed subtle induration involving the right peripheral zone of the prostate without fixation.&lt;/p&gt;&lt;p&gt;Multiparametric magnetic resonance imaging (MRI) of the prostate demonstrated a 1.9-cm lesion characterized as a Prostate Imaging-Reporting and Data System score of 5 (&lt;i&gt;very high&lt;/i&gt; likelihood of significant cancer). It was located within the right posterior peripheral zone at the mid-gland, without radiographic evidence of extracapsular extension or seminal vesicle invasion. No suspicious pelvic lymph nodes were identified.&lt;/p&gt;&lt;p&gt;Transrectal ultrasound–guided, systematic and MRI-targeted biopsies were subsequently performed. Pathologic sampling included a systematic 12-core biopsy sampling of the entire prostate, from which seven of 12 cores were positive. The biopsy was enhanced by MRI-informed targeting of the aforementioned lesion with a Prostate Imaging-Reporting and Data System score of 5 and yielded two of three positive cores. Of all biopsies, the highest Gleason score was 4 + 3 = 7, representing an intermediate grade and correlating to International Society of Urological Pathology (ISUP) grade group 3,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; with pattern 4 in approximately 60% and no cribriform features. Perineural invasion was present, and overall tumor involvement ranged from 20% to 70% within positive cores. Based on these findings, the patient was staged with clinical T2b, N0, M0 (cT2bN0M0) disease.&lt;/p&gt;&lt;p&gt;According to National Comprehensive Cancer Network (NCCN) criteria, the patient was classified as having unfavorable intermediate-risk (UIR) prostate cancer based on the presence of ISUP grade group 3&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; adenocarcinoma and ≥50% of cores that were positive for cancer. Staging with prostate-specific membrane antigen–positron emission tomography demonstrated no evidence of nodal or distant metastatic disease.&lt;/p&gt;&lt;p&gt;The patient was evaluated in a multidisciplinary clinic and expressed interest in definitive radiation therapy (RT) over surgery. Given his UIR disease, standard management options included RT al","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daraxonrasib significantly improves overall and progression-free survival in patients with previously treated metastatic pancreatic cancer Daraxonrasib显著提高既往治疗的转移性胰腺癌患者的总生存期和无进展生存期
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-08-19 DOI: 10.3322/caac.70097
Carrie Printz
{"title":"Daraxonrasib significantly improves overall and progression-free survival in patients with previously treated metastatic pancreatic cancer","authors":"Carrie Printz","doi":"10.3322/caac.70097","DOIUrl":"https://doi.org/10.3322/caac.70097","url":null,"abstract":"&lt;p&gt;Few therapies are available for patients with previously treated metastatic pancreatic ductal adenocarcinomas (mPDACs), and those that exist offer limited benefit while causing toxic side effects. The median overall survival (OS) for patients with the disease is less than 1 year.&lt;/p&gt;&lt;p&gt;More than 90% of PDAC cases, including mPDAC, have mutations in the &lt;i&gt;KRAS&lt;/i&gt; gene, and researchers have long sought a way to effectively target them. Although some targeted therapies for the mutation exist, they are limited to rare molecular subgroups.&lt;/p&gt;&lt;p&gt;Scientists have developed new types of &lt;i&gt;RAS&lt;/i&gt;(ON) multiselective inhibitors to target a broader range of variants and to improve outcomes for patients with hard-to-treat cancers. In the phase 3 RASolute 302 trial, the &lt;i&gt;RAS&lt;/i&gt;(ON) inhibitor daraxonrasib demonstrated significant, unprecedented improvements in both OS and progression-free survival (PFS) for patients with mPDAC.&lt;/p&gt;&lt;p&gt;The international phase 3 trial compared daraxonrasib to chemotherapy in 500 patients with mPDAC. Results showed nearly a doubling of survival with fewer side effects in patients treated with daraxonrasib versus chemotherapy.&lt;/p&gt;&lt;p&gt;“We have never seen survival like this before in patients with advanced pancreas cancer who have progressed on one line of chemotherapy, so it will absolutely be landscape-changing for therapeutic options,” says Rachna Shroff, MD, chief of the Division of Hematology/Oncology at the University of Arizona Cancer Center in Tucson. “This is a game changer for pancreas cancer.”&lt;/p&gt;&lt;p&gt;The research was presented at the 2026 American Society of Clinical Oncology Annual Meeting and was published simultaneously in &lt;i&gt;The New England Journal of Medicine&lt;/i&gt; (doi:10.1056/NEJMoa2605555).&lt;/p&gt;&lt;p&gt;Daraxonrasib is an oral &lt;i&gt;RAS&lt;/i&gt;(ON) multiselective, tricomplex inhibitor of the active guanosine triphosphate–bound state of mutant and wild-type &lt;i&gt;RAS&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;The open-label, randomized trial assigned patients previously treated for mPDAC to receive either once daily oral daraxonrasib or chemotherapy of the investigator’s choice. The dual primary endpoints were OS and PFS in the subpopulation of patients with &lt;i&gt;RAS&lt;/i&gt; G12 mutations (91.8% of patients).&lt;/p&gt;&lt;p&gt;The overall study population included patients with &lt;i&gt;RAS&lt;/i&gt; G12, G13, or Q61 mutations as well as those with no identified &lt;i&gt;RAS&lt;/i&gt; mutation. Key secondary endpoints included OS and PFS in the overall population along with objective responses and patient-reported quality of life in the &lt;i&gt;RAS&lt;/i&gt; G12 and overall populations. Investigators also assessed safety.&lt;/p&gt;&lt;p&gt;In the study population, 248 patients received daraxonrasib, and 252 patients received chemotherapy. For patients in the &lt;i&gt;RAS&lt;/i&gt; G12 group, the median OS was 13.2 months with daraxonrasib and 6.6 months with chemotherapy. In the overall population, the median OS was 13.2 and 6.7 months, respectively. In both groups, the hazard ratio was 0.40 (&lt;i&gt;p&lt;/i&gt; &lt; .001).&lt;/p&gt;&lt;p&gt;For patients wi","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastasis-directed radiation therapy may improve progression-free survival in patients with oligometastatic solid tumors 转移性放射治疗可能改善少转移性实体瘤患者的无进展生存期
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-08-19 DOI: 10.3322/caac.70098
Carrie Printz
{"title":"Metastasis-directed radiation therapy may improve progression-free survival in patients with oligometastatic solid tumors","authors":"Carrie Printz","doi":"10.3322/caac.70098","DOIUrl":"https://doi.org/10.3322/caac.70098","url":null,"abstract":"&lt;p&gt;In recent years, scientists have learned that patients with a limited number of metastases (i.e., oligometastatic cancers) experience improved progression-free survival (PFS) outcomes with the addition of stereotactic ablative radiosurgery directed to those metastases. These findings were demonstrated by the phase 2, randomized SABR-COMET trial (doi:10.1200/JCO.20.00818).&lt;/p&gt;&lt;p&gt;Although SABR-COMET assessed patients with many different cancers, a new phase 2 study, EXTEND, sought to determine which patients with specific cancers would benefit from a similar type of metastasis-directed therapy (MDT) approach in combination with standard-of-care (SOC) systemic therapy.&lt;/p&gt;&lt;p&gt;Findings indicated that adding MDT radiation therapy to SOC for oligometastatic disease improved PFS for patients with pancreatic, prostate, and other cancers. However, results for breast and kidney cancers were inconclusive.&lt;/p&gt;&lt;p&gt;The study was published in the &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt; (doi:10.1200/JCO-25-02856).&lt;/p&gt;&lt;p&gt;The multicenter, phase 2 EXTEND trial randomized patients to MDT plus SOC or SOC alone in one of six histology-specific baskets: breast, pancreas, kidney, two prostate baskets, and one “other” basket. PFS was the primary endpoint. Exploratory endpoints were ctDNA and immune profiling.&lt;/p&gt;&lt;p&gt;Eligible patients had one to five metastases, had received no more than four prior lines of systemic therapy for metastatic disease, and had a diagnosis within one of 12 specified histologies.&lt;/p&gt;&lt;p&gt;Between 2018 and 2023, 350 patients were randomized, and 334 were analyzed: MDT plus SOC (&lt;i&gt;n&lt;/i&gt; = 166) and SOC (&lt;i&gt;n&lt;/i&gt; = 168). MDT could include radiotherapy, resection, or ablation. Radiotherapy was used as MDT for 98% of metastases (370 of 379). At a median follow-up of 53 months, PFS was significantly longer with MDT plus SOC (hazard ratio [HR], 0.54; 95% CI, 0.41–0.72; &lt;i&gt;p&lt;/i&gt; &lt; .001). PFS also improved when the prostate baskets were excluded (HR, 0.60; 95% CI, 0.40–0.89).&lt;/p&gt;&lt;p&gt;The pancreas, prostate, and “other” baskets had superior PFS with MDT plus SOC, but the breast and kidney baskets were inconclusive.&lt;/p&gt;&lt;p&gt;Patients with detectable ctDNA at enrollment had shorter PFS and overall survival. Conversely, if ctDNA clearance occurred 3 months after enrollment, survival rates were improved. Findings also showed that patients treated with MDT plus SOC had improved clearance of ctDNA. The authors noted that these findings point to the important role that the addition of MDT may play in treating oligometastatic cancer.&lt;/p&gt;&lt;p&gt;In addition, immune activation induced by MDT plus SOC was most pronounced among baskets with superior PFS, and this indicates another area that warrants investigation.&lt;/p&gt;&lt;p&gt;Because pancreatic and prostate cancers showed the greatest promise with MDT plus SOC, researchers have initiated the phase 3 EXPAND trial in pancreatic cancer. Other independent research efforts are underway in prostate cancer. Findings in the “other” basket also ","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Serious mental illness and cancer: A call to action for equitable care” 更正“严重精神疾病和癌症:呼吁采取行动争取公平护理”
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-07-30 DOI: 10.3322/caac.70101
{"title":"Correction to “Serious mental illness and cancer: A call to action for equitable care”","authors":"","doi":"10.3322/caac.70101","DOIUrl":"https://doi.org/10.3322/caac.70101","url":null,"abstract":"<p>McFarland D, Bergerot C, Bidstrup P, et al. Serious mental illness and cancer: a call to action for equitable care. <i>CA Cancer J Clin</i>. 2026;e70095. doi:10.3322/caac.70095</p><p>An author’s first name was misspelled in the original publication. The sixth author’s name should read Shahrzad Zamani.</p><p>The authors apologize for this error.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accurate data as the foundation of equitable cancer control: Lessons from global cancer statistics 2024 and the complexity of ovarian cancer 准确的数据作为公平癌症控制的基础:来自2024年全球癌症统计的教训和卵巢癌的复杂性
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-07-17 DOI: 10.3322/caac.70096
Christina R. Washington MD, Kathleen N. Moore MD, MS, Isabelle L. Ray-Coquard MD, PhD
{"title":"Accurate data as the foundation of equitable cancer control: Lessons from global cancer statistics 2024 and the complexity of ovarian cancer","authors":"Christina R. Washington MD,&nbsp;Kathleen N. Moore MD, MS,&nbsp;Isabelle L. Ray-Coquard MD, PhD","doi":"10.3322/caac.70096","DOIUrl":"https://doi.org/10.3322/caac.70096","url":null,"abstract":"&lt;p&gt;In this issue of &lt;i&gt;CA: A Cancer Journal for Clinicians&lt;/i&gt;, Sung and colleagues present global cancer statistics 2024, the latest in the GLOBOCAN series produced by the International Agency for Research on Cancer.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; They estimate 20.6 million new cancer cases and 9.8 million cancer deaths worldwide in 2024, equivalent to one in five people developing cancer in their lifetime, and project that the annual burden will reach 31.5 million cases by 2050, a 53% increase driven largely by population growth and aging.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The largest proportional increases will fall on low Human Development Index (HDI) and medium-HDI countries, &lt;i&gt;where the number of new cases is projected to roughly double&lt;/i&gt;. The value of these figures for setting screening, prevention, and treatment policy depends on the accuracy of the data used to generate them. This accuracy is weakest in parts of the world where the cancer burden is projected to grow fastest.&lt;/p&gt;&lt;p&gt;Sung and colleagues are explicit about this limitation. They note that only about one in three countries reports high-quality incidence data to the International Agency for Research on Cancer's Cancer Incidence in Five Continents, whereas only one in four countries reports high-quality national mortality data to the World Health Organization.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Population-based cancer registries (PBCRs) capture a small fraction of the population across much of sub-Saharan Africa and Asia, and national vital statistics systems frequently suffer from incomplete coverage and from reliance on nonspecific causes of death that must be statistically redistributed.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; Therefore, the 2024 estimates are best understood as a synthesis of observed data, short-term prediction, and modeled mortality-to-incidence ratios, largely extrapolated from data collected before 2020.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The robustness of that synthesis varies widely by region, and this variability can affect the global estimates on which policymakers, funders, and clinicians base their decisions.&lt;/p&gt;&lt;p&gt;These limitations have practical consequences. When the two principal global frameworks, GLOBOCAN and the Global Burden of Disease Study, disagree on basic questions such as which cancer is most commonly diagnosed worldwide, the discrepancy arises from differences in data processing, modeling strategy, and the redistribution of ill-defined mortality codes rather than from differences in underlying biology.&lt;span&gt;&lt;sup&gt;1, 4&lt;/sup&gt;&lt;/span&gt; Most registries also lack individual-level data on socioeconomic status, a key surrogate for the social determinants that drive much of the variation in incidence and outcome, and this limits how meaningfully registry data can be translated into targeted intervention.&lt;/p&gt;&lt;p&gt;Global cancer statistics 2024 illustrates why data annotation beyond only incidence and mortality matters. The report documents a marked decoupling of incidence and mortality by HD","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148467528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries 2024年全球癌症统计:GLOBOCAN估计全球186个国家34种癌症的发病率和死亡率。
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-07-08 DOI: 10.3322/caac.70090
Hyuna Sung PhD, Adalberto M. Filho PhD, Mathieu Laversanne Msc, Jacques Ferlay ME, Rebecca L. Siegel MPH, Isabelle Soerjomataram MD, MSc, PhD, Ahmedin Jemal DVM, PhD, Freddie Bray BSc, MSc, PhD
{"title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","authors":"Hyuna Sung PhD,&nbsp;Adalberto M. Filho PhD,&nbsp;Mathieu Laversanne Msc,&nbsp;Jacques Ferlay ME,&nbsp;Rebecca L. Siegel MPH,&nbsp;Isabelle Soerjomataram MD, MSc, PhD,&nbsp;Ahmedin Jemal DVM, PhD,&nbsp;Freddie Bray BSc, MSc, PhD","doi":"10.3322/caac.70090","DOIUrl":"10.3322/caac.70090","url":null,"abstract":"<p>This article provides updated global cancer statistics for the year 2024 based on the GLOBOCAN estimates of the International Agency for Research on Cancer. The authors describe national cancer incidence and mortality by world region and the Human Development Index and predict the burden in 2050 based on demographic trends. In 2024, an estimated 20.6 million new cancer cases (19.5 million excluding nonmelanoma skin cancer) and 9.8 million deaths (9.7 million excluding nonmelanoma skin cancer) occurred worldwide, equivalent to one in five people developing cancer during their lifetime and one in nine men and one in 13 women dying from the disease. Lung cancer is the most frequently diagnosed cancer, responsible for almost 2.6 million new cases (12.8%), followed by female breast (11.8%), colorectal (9.9%), prostate (7.5%), and stomach (4.7%) cancer. Lung cancer is also the leading cause of cancer death, with an estimated 1.9 million deaths (19.1%), followed by colorectal (9.4%), liver (7.5%), female breast (7.1%), and stomach (6.6%) cancer. Incidence rates vary four- to five-fold across regions, with the highest rates found in Australia/New Zealand (men, 477 per 100,000; women, 396 per 100,000), whereas mortality rates differ two-fold, with elevated rates in Eastern Europe for men (158 per 100,000) and Melanesia for women (108 per 100,000). The incidence burden is predicted to reach 34.4 million by 2050, up 67% from 2024, with the largest proportional increases in lower Human Development Index countries. Although global variation in cancer profiles demands a nuanced approach to cancer control at national and regional levels, primary prevention must be at the forefront, including intensified efforts to reduce tobacco use, prevent infections, lower alcohol consumption and excess body weight, and increase physical activity.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148402980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serious mental illness and cancer: A call to action for equitable care 严重精神疾病和癌症:呼吁采取行动争取公平护理。
IF 685.2 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2026-07-03 DOI: 10.3322/caac.70095
Daniel McFarland DO, MS, Cristiane Bergerot PhD, Pernille Bidstrup PhD, Miri Cohen PhD, Paul D’Alton PhD, Shahrzhad Zamani DO, Louise Mullen MSc, Michelle Riba MD, MS, Luigi Grassi MD, Kelly Irwin MD, MPH
{"title":"Serious mental illness and cancer: A call to action for equitable care","authors":"Daniel McFarland DO, MS,&nbsp;Cristiane Bergerot PhD,&nbsp;Pernille Bidstrup PhD,&nbsp;Miri Cohen PhD,&nbsp;Paul D’Alton PhD,&nbsp;Shahrzhad Zamani DO,&nbsp;Louise Mullen MSc,&nbsp;Michelle Riba MD, MS,&nbsp;Luigi Grassi MD,&nbsp;Kelly Irwin MD, MPH","doi":"10.3322/caac.70095","DOIUrl":"10.3322/caac.70095","url":null,"abstract":"<p>Cancer advances are not distributed equitably among many segments of the population. Specifically, individuals with serious mental illness (SMI) face compounded disparities in cancer detection, treatment, and survival. SMI, characterized by conditions such as schizophrenia, bipolar disorder, and severe major depression, is associated with significant functional impairment and a two-to-three-decade reduction in life expectancy. Patients with SMI encounter unique challenges when navigating cancer care, including fragmented care pathways, less access to cancer therapeutics, limited psychosocial support, stigma, heightened vulnerability to diagnostic overshadowing where symptoms are attributed to their psychiatric rather than a medical or oncologic condition, and underrepresentation in therapeutic clinical trials. This review explores the intersection of SMI and cancer care starting with the conceptual background and its importance related to cancer outcomes and the delivery of ethical care to highlight unmet needs and a multitude of barriers. The paper proposes practical recommendations to improve cancer care for individuals with SMI who develop cancer including adopting the collaborative care model, enhancing psychosocial and psychiatric integration in oncology settings, and addressing biases inherent in clinician training. Interventions targeting individual, interpersonal, health system, and policy levels are essential to comprehensively mitigating disparities and developing durable cancer delivery strategies. Equitable cancer care for patients with SMI is both a moral imperative and a cornerstone of advancing social justice in oncology. Thus, there is a critical need to prioritize the translation of research advances, to close the gap in cancer outcomes and mortality, and to improve patient outcomes and wellbeing.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 4","pages":""},"PeriodicalIF":685.2,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148373657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书